Is Intellia Therapeutics, Inc. (NTLA) A Good Stock To Buy Now?

Is NTLA a good stock to buy? We came across a bullish thesis on Intellia Therapeutics, Inc. on Markman Capital Insight’s Substack. In this article, we will summarize the bulls’ thesis on NTLA. Intellia Therapeutics, Inc.’s share was trading at $16.61 as of June 29th.

Pressmaster/Shutterstock.com

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. NTLA is emerging as...